相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel synthetic treatment options for migraine
Andrea Negro et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
The Risks or Lack Thereof of Migraine Treatments in Vascular Disease
Hans-Christoph Diener
HEADACHE (2020)
Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans
Serena Ghanshani et al.
HEADACHE (2020)
Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data
David W. Dodick et al.
JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH (2020)
Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies
Luis Hermenegildo Martin Arias et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Triptans for Migraine Patients With Vascular Risks: New Insights, New Options
Elizabeth Leroux et al.
HEADACHE (2019)
Meningeal contribution to migraine pain: a magnetic resonance angiography study
Sabrina Khan et al.
BRAIN (2019)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data
Karin Zebenholzer et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study
Dawn C. Buse et al.
HEADACHE (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people
David Braunstein et al.
CEPHALALGIA (2015)
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies
G. Roberto et al.
CEPHALALGIA (2015)
Triptan use in Italy: Insights from administrative databases
Roberto Da Cas et al.
CEPHALALGIA (2015)
Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database
Giuseppe Roberto et al.
CEPHALALGIA (2014)
Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy
Chiara Biagi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Prevalence of headache in Europe: a review for the Eurolight project
Lars Jacob Stovner et al.
JOURNAL OF HEADACHE AND PAIN (2010)
Acute Myocardial Infarction With Sumatriptan: A Case Report and Review of the Literature
Flavio Devetag Chalaupka
HEADACHE (2009)
Migraine prevalence, disease burden, and the need for preventive therapy
R. B. Lipton et al.
NEUROLOGY (2007)
Frovatriptan use in migraineurs with or at high risk of coronary artery disease
AH Elkind et al.
HEADACHE (2004)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Triptans in migraine - The risks of stroke, cardiovascular disease, and death in practice
GC Hall et al.
NEUROLOGY (2004)
Effect of high-dose intravenous eletriptan on coronary artery diameter
JA Goldstein et al.
CEPHALALGIA (2004)
The prevalence of migraine in women aged 40-74 years:: a population-based study
P Mattson et al.
CEPHALALGIA (2000)
Prevalence of migraine and non-migrainous headache - head-HUNT, a large population-based study
K Hagen et al.
CEPHALALGIA (2000)
分享论文
